JAGX (Jaguar Health) EBITDA Margin %: 49.10% (As of Mar. 2026)

What is Jaguar Health EBITDA Margin %?

Jaguar Health JAGX +9.73% 22 EBITDA Margin % is 49.10% as of Mar. 2026. GuruFocus rates JAGX with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, Jaguar Health ranks worse than 54.13% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Jaguar Health's EBITDA for the three months ended in Mar. 2026 was $9.94 Mil. Jaguar Health's Revenue for the three months ended in Mar. 2026 was $20.25 Mil. Therefore, Jaguar Health's EBITDA margin for the quarter that ended in Mar. 2026 was 49.10%.

Jaguar Health (NAS:JAGX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Jaguar Health EBITDA Margin % Related Terms

Jaguar Health EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Jaguar Health's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jaguar Health EBITDA Margin % Chart

Jaguar Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBITDA Margin %

Get a 7-Day Free Trial

-977.30

-279.19

-339.42

-313.65

-449.38

Jaguar Health Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBITDA Margin %	Get a 7-Day Free Trial															-400.86	-250.12	-216.70	-887.82	49.10

JAGX vs BBLG, VBIO, PKTX: EBITDA Margin % Comparison

For the Biotechnology subindustry, Jaguar Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jaguar Health EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jaguar Health's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Jaguar Health's EBITDA Margin % falls into.

Save Embed

22GF Score

Jaguar Health Inc JAGX

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Jaguar Health EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Jaguar Health's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-51.728	/	11.511
	=	-449.38 %

Jaguar Health's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	9.942	/	20.247
	=	49.10 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of 49.10% mean?

Jaguar Health (JAGX) has a EBITDA Margin % of 49.10% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jaguar Health and its competitors. According to the industry distribution chart, Jaguar Health ranks #511 out of 944 companies in the Biotechnology industry, placing it in the top 54.1%.

Is Jaguar Health's EBITDA Margin % too high?

Jaguar Health's current EBITDA Margin % is 49.10%. Based on the distribution chart, Jaguar Health ranks #511 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jaguar Health has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.

How does Jaguar Health's EBITDA Margin % compare to BBLG and VBIO?

According to the Biotechnology industry distribution chart, Jaguar Health ranks #511 out of 944 companies for EBITDA Margin %. This places Jaguar Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jaguar Health and its competitors. Jaguar Health's current EBITDA Margin % is 49.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Jaguar Health stock overvalued right now?

Jaguar Health (JAGX) has a current EBITDA Margin % of 49.10%. The current EBITDA Margin % is 49.10%. Jaguar Health's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Jaguar Health (JAGX), the current EBITDA Margin % is 49.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jaguar Health Business Description

Industry Healthcare Biotechnology

Comparable Companies BBLG VBIO PKTX CASIF SLXN OGEN ELOX CPMV HEPA AXIM VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 200 Pine Street, Suite 400, San Francisco, CA, USA, 94104

Website http://www.jaguar.health

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

22GF Score

Get the complete analysis for JAGX

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.95

Price

View JAGX Analysis

See EBITDA Margin % data for all stocks →